LATEST TWEETS - CURATED BY HASH FINANCE

$YTEN Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Unique Aspects of the Company’s GRAIN… https://t.co/5HhTkXHQZl
Announcement: Yield10 CSO Dr. Kristi Snell to highlight unique aspects of the company’s GRAIN Technology Platform t… https://t.co/bsF58jYJOt
⚡AiMS (ez_alertz) 15 hours ago
$YTEN Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Unique Aspects of the Company’s GRAIN… https://t.co/2aVht9PPf5
$YTEN speaking next Tuesday at AgBio Congress at 11:40AM => https://t.co/j5ln6MaAz5 #Yield10 #Agriculture #CRISPR… https://t.co/hkTzM1I9gh
Yield10 Bioscience Inc $YTEN Given Consensus Rating of “Strong Buy” by Brokerages https://t.co/0Z22LvYJEG #stocks
$YTEN The First Gene-Edited Food Is Now Being Served => https://t.co/9qyCO8IUyf #Yield10 #GeneEdited #Food #CRISPR… https://t.co/AWV6Zqx6k6
To sign up for email alerts including press releases, SEC filings and calendar events, please visit: https://t.co/bV8z5332iZ $YTEN
$YTEN Yield10 Bioscience Files U.S. Patent Application Covering New Technology ... https://t.co/g3PoP8B8dj #Yield10… https://t.co/NTREcygPL1
$YTEN Owner paid 1.16 for over 4M shares. Bargain here in the .80’s.
$YTEN Yield10 Bioscience Files U.S. Patent Application Covering New Technology Enabling Low-cost Production of PHA-… https://t.co/mdcb1o9jlz
JACK WOLF (JackWolf57) 1 week ago
Yield10 Bioscience Files U.S. Patent Application Covering New Technology Enabling Low-cost Production of PHA-based… https://t.co/MspWQAHZBn
Yield10 Bioscience Files U.S. Patent Application Covering New Technology Enabling Lowcost Production of PHAbased Bi… https://t.co/qrAEuoKEaN
Announcement: Yield10 Bioscience Files U.S. Patent Application Covering New Technology Enabling Low-cost Production… https://t.co/p7hmwenjka
$YTEN Yield10 Bioscience Files U.S. Patent Application Covering New Technology Enabling Low-cost Production of PHA-… https://t.co/aH41YubWTz
Yield10 Bioscience $YTEN Earns Sell Rating from Zacks Investment Research https://t.co/4rBdEYVrfm
Zacks Investment Research Reaffirms Sell Rating for Yield10 Bioscience $YTEN https://t.co/Pp0SjlrUCq